Skip to main content
. 2013 Jan 10;137(3):903–913. doi: 10.1007/s10549-012-2400-2

Fig. 1.

Fig. 1

Design of SWOG 0221, a trial for women with high-risk breast cancer A doxorubicin, C cyclophosphamide, G filgrastim, PEGG pegfilgrastim, T paclitaxel